SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges QuidelOrtho Corporation (NASDAQ:QDEL) investors who suffered substantial losses to submit your losses now.
Class Period: Feb. 18, 2022 – Apr. 1, 2024
Lead Plaintiff Deadline: June 11, 2024
Visit: www.hbsslaw.com/investor-fraud/QDEL
Contact An Attorney Now: QDEL@hbsslaw.com
844-916-0895
QuidelOrtho Corporation (NASDAQ:QDEL) Securities Class Action:
The litigation is focused on the propriety of QuidelOrtho's past assurances about its preparedness to maintain a stable high margin revenue stream from its respiratory business in the face of the COVID-19 pandemic becoming an endemic and about its FDA submission for its purported "next flagship product" (the "Savanna RVP4 Test") being "on track."
The complaint alleges QuidelOrtho misled investors by making statements that were false and misleading because it knew or deliberately disregarded that: (1) it sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (2) excess inventories of COVID-19 tests existed throughout the supply chain; (3) as a result, its distributor and pharmacy chain customers were poised to ...
QDEL) Securities Fraud Class Action Filed After QDEL Reports Disastrous Q4 2023 Results, Terminates CEO, Withdraws FDA Submission - Hagens Berman>Full story available on Benzinga.com